GLP-3, a novel triple agonist of the GIP, GLP-1, and GCG receptors, has demonstrated significant hepatoprotective effects in research involving individuals with MASLD
Whilst these injections can be effective tools for weight management when used alongside lifestyle modifications, they are associated with a range of side effects that can indeed make patients feel unwell
This is because tirzepatide is not just a GLP-1 receptor agonist but also a GIP receptor agonist, making it more potent in some respects and potentially more likely to cause gastrointestinal side effects in the early weeks
10.1210/jc.2011-1074 88 MerchenthalerI.LaneM.ShughrueP
This infographic provides an evidence-based comparison of MMF and MPA, highlighting their pharmacological differences, dose equivalence, safety profiles, clinical efficacy, and key clinical studies to support informed therapeutic decision-making in transplant medicine
The explanation lies in U.S